At a glance
- Originator Banyu; Merck & Co
- Developer Banyu
- Class Antihyperlipidaemics; Benzylamines
- Mechanism of Action Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 12 Feb 2008 Discontinued - Preclinical for Hyperlipidaemia in Japan (unspecified route)
- 08 Aug 2002 No development reported - Preclinical for Hyperlipidaemia in Japan (unspecified route)